Clinical Trials Browser

Pancreatic Neoplasms × Bevacizumab × 1 year × Clear all

Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT06400472 2026-01-14

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05005403 2025-10-28

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab

Phase 1 Recruiting

512 enrolled

BreastGastrointestinalHead & NeckThoracic

Anophthalmia with pulmonary hypoplasia, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT06313970 2025-09-03

First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients

Phase 2 Recruiting

58 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04925284 2025-04-04

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

Phase 1 Completed

269 enrolled

BreastGastrointestinalGynecologicThoracic

Carcinoma, Ovarian Epithelial, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Pancreatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)